| Literature DB >> 19816589 |
Haijun Li1, Peizeng Yang, Zhengxuan Jiang, Shengping Hou, Lin Xie.
Abstract
PURPOSE: Interferon regulation factor 5 (IRF5) is a member of the IRF family of transcription factors that control the transactivation of type I interferon system-related genes as well as the expression of several other genes involved in immune response. Here, we investigated its association with Behcet's disease (BD) in a well defined group of Chinese Han patients.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19816589 PMCID: PMC2759328
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
The primers and enzymes used for PCR-RFLP genotyping.
| 5′-CGTGGTCACATTGGTGATGCTC-3′ | 5′-GGCTCTTCTCTCCAAGGCAGACA-3′ | BSMFI | |
| 5′-AAGGTGCCCAGAAAGAAGCTTCTTAC-3′ | 5′-GCACTGGGAAATCACCCCTTTT-3′ | BCEAI |
The details of the primers and enzymes used for PCR-RFLP genotyping.
Genotype and allele distributions of IRF5 rs2280714 and rs752637 polymorphisms in BD patients and controls.
| AA | 51 (56.1) | 60 (54.9) | 0.233 | ||
| | AG | 74 (66.7) | 58 (65.3) | 0.233 | |
| | GG | 27 (29.3) | 31 (28.7) | 0.233 | |
| | A | 176 (57.9) | 178 (59.7) | 0.647 | 0.927 (0.670–1.283) |
| | G | 128 (42.1) | 120 (40.3) | 0.647 | 1.079 (0.780–1.493) |
| AA | 64 (59.0) | 49 (54.0) | 0.266 | ||
| | AG | 68 (68.4) | 63 (62.6) | 0.266 | |
| | GG | 20 (24.5) | 27 (22.5) | 0.266 | |
| | A | 196 (64.5) | 161 (57.9) | 0.105 | 1.319 (0.944–1.843) |
| G | 108 (35.5) | 117 (42.1) | 0.105 | 0.758 (0.543–1.059) |
BD=Behcet’s disease, OR=odds ratio, 95% CI=95% confidence interval. The genotype and allele distributions of IRF5 rs2280714 and rs752637 polymorphisms in BD patients and controls. No significant differences of the genotype and allele distributions were found between patients and controls.
The clinical manifestations of BD patients.
| Uveitis | 152 | 1% |
| Oral ulcer | 127 | 0.836% |
| Genital ulcer | 64 | 0.421% |
| Hypopyon | 41 | 0.27% |
| Skin lesions | 84 | 0.553% |
| Arthritis | 43 | 0.283% |
N=number of patients; BD=Behcet’s disease. This table summarizes the proportion of clinical manifestations in relation to the BD patients